DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 as a Promising Treatment for Ovarian Cancer October 19, 2015 • 7:00 AM EDT
DelMar Pharmaceuticals to Present at the 14th Annual BIO Investor Forum October 14, 2015 • 8:00 AM EDT
DelMar Pharmaceuticals Launches Digital Corporate Communication Channels October 13, 2015 • 8:00 AM EDT
DelMar Pharmaceuticals to Present Data on the Promising Potential of VAL-083 in the Treatment of Pediatric Brain Tumors September 29, 2015 • 7:00 AM EDT
DelMar Pharmaceuticals to Present an Interactive Live Webcast at VirtualInvestorConferences.com on October 1, 2015 September 28, 2015 • 8:21 AM EDT
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme at GBM2015 September 10, 2015 • 7:05 AM EDT
DelMar Pharmaceuticals Presents Clinical Protocol for Advancement of VAL-083 into Phase IV Studies as a Treatment for Non-Small Cell Lung Cancer September 8, 2015 • 11:30 AM EDT
DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update September 4, 2015 • 7:30 AM EDT
DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer September 2, 2015 • 8:05 AM EDT
DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 August 27, 2015 • 8:05 AM EDT